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Abstract 53 
Background 54 
Thyroid eye disease is a disabling inflammatory orbital condition which causes visual 55 
dysfunction and psychological morbidity. Standard treatment is with systemic corticosteroids, 56 
but the additional benefit of orbital radiotherapy and antiproliferative immunosuppression is 57 
unclear.  58 
 59 
Methods  60 
Participants all received a  24 week course of oral prednisolone and were also randomised to 61 
receive radiotherapy or sham-radiotherapy, and azathioprine or placebo, in a 2x2 factorial 62 
design. The primary outcomes were a binary composite clinical outcome score and 63 
ophthalmopathy index at 48 weeks and clinical activity score at 12 weeks. (ISRCTN 64 
22471573).   65 
 66 
Findings 67 
126 adults with active moderate-to-severe thyroid eye disease were randomised. 103 68 
provided outcome data, of which 84 completed their allocated treatment of  radiotherapy or 69 
sham-radiotherapy, and 57 continued to take azathioprine or placebo until 48 weeks. Pre-70 
specified intention-to-treat analysis of the binary clinical composite outcome measure 71 
revealed an odds of improvement for azathioprine of OR(adj)=2·56 (95%CI 0·98, 6·66; 72 
p=0·05) and for radiotherapy of OR(adj)=0·89 (95%CI 0·36, 2·23; p=0·80). In a post-hoc 73 
analysis of patients completing their allocated therapy, improvement was more frequent on 74 
azathioprine (OR(adj)=6·83; 95%CI 1·66, 28.1; p=0·008 than radiotherapy (OR(adj)=0·71; 75 
95%CI 0·26, 1·95; p=0·50).  The ophthalmopathy index, clinical activity score and number 76 
of adverse events (azathioprine N=161, radiotherapy N=156) did not differ between treatment 77 
groups. 78 
 79 
Interpretation  80 
In patients receiving oral prednisolone for 24 weeks, the addition of radiotherapy was not 81 
beneficial. With regard to azathioprine, our conclusions are limited by a high number of 82 
withdrawals from treatment. However, these results suggest that disease severity at 48 weeks 83 
was reduced in participants who completed azathioprine treatment. 84 
  85 
Funding 86 
National Eye Research Centre, Above and Beyond and Moorfields Eye Charity, supported by 87 
infrastructural investment from the National Institute for Health Research  88 
 89 
  90 
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  91 Research in Context 
 Active moderate-to-severe thyroid eye disease is currently treated with systemic corticosteroids, but 
outcomes are often sub-optimal. Corticosteroids are most effective when administered intravenously, 
but this is inconvenient, and oral administration remains common in global clinical practice. However, 
uncertainty remains about the additional benefit of orbital radiotherapy and antiproliferative 
immunosuppressive drugs.  
 
Evidence before this study 
Previous retrospective case series have reported that the antiproliferative immunosuppressive drug 
azathioprine reduces disease severity and the need for rehabilitative surgery, but no prior RCTs have 
been completed. The evidence base for orbital radiotherapy is stronger, but conflicting, especially in 
the context of systemic corticosteroid treatment.  
 
Added value of this study 
Eighty per cent of subjects completed radiotherapy, but no significant short (12 week) or long-term 
(48 week) benefit resulted over and above the improvement seen with a 24-week tapering course of 
oral corticosteroids.  Less strong conclusions can be drawn with regard to azathioprine, as many 
patients did not complete treatment due to abnormalities in monitoring blood tests or side-effects, but 
those that continued azathioprine for more than 24 weeks benefitted, predominantly due to a 
prevention of deterioration after the end of corticosteroid treatment.  
 
Implications of all the available evidence 
These results do not support the use of radiotherapy in thyroid eye disease in patients also treated with 
systemic corticosteroids. They also provide evidence in favour of the use of anti-proliferative 
immunosuppressive agents such as azathioprine beyond the period of corticosteroid therapy to 
improve long-term clinical outcomes. 
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Introduction 92 
Active moderate-to-severe thyroid eye disease, also known as Graves’ orbitopathy or thyroid 93 
associated orbitopathy) occurs in 5-10% of cases of Graves’ disease(1). It can be both 94 
visually disabling and cosmetically disfiguring and substantially impairs quality of life(1-3). 95 
The aim of treatment is to suppress orbital inflammation and reduce consequent tissue re-96 
modelling in extraocular muscles, orbital fat and other periocular soft tissues(4, 5). 97 
Immunosuppressive therapies, in particular corticosteroids(1, 4, 6), are the mainstay of 98 
treatment for active moderate-to-severe thyroid eye disease (1). However, they are typically 99 
withdrawn after 24 weeks of treatment to limit cumulative toxicity regardless of whether they 100 
are administered via the oral or intravenous route(7), and given that active disease lasts 1–2 101 
years, recurrence at the time of withdrawal often occurs(1, 7-9).   102 
 103 
Consequently, the avoidance of corticosteroid side-effects, improvement in treatment efficacy 104 
and maintenance of long-term disease control are major goals for the field of thyroid eye 105 
disease as a whole. However, efforts to use monoclonal antibody therapies to more 106 
selectively suppress disease are still either early in their route to market(10), or have failed to 107 
demonstrate definitive treatment benefit(11, 12). Hence, given the proven short-term efficacy 108 
of corticosteroids in the treatment of active moderate-to-severe thyroid eye disease, it is 109 
likely that they will remain the gold-standard first-line treatment for several years to come, 110 
and the need to find adjunctive therapies to augment and sustain their benefit remains very 111 
real. 112 
 113 
To date, the only non-corticosteroid conventional immunosuppressant drug to have been 114 
evaluated in RCTs is cyclosporine A(13, 14), which was found to be beneficial, but its use 115 
has not been widely adopted because of concerns about side-effects(6). An alternative 116 
strategy is to use an antiproliferative agent such as azathioprine as it is better tolerated than 117 
cyclosporine A(15, 16) and although ineffective as monotherapy(17), retrospective data 118 
indicates that in combination with corticosteroids it reduces disease severity and the need for 119 
rehabilitative surgery(18).  In addition to immunosuppression, non-pharmaceutical treatment 120 
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of active thyroid eye disease  with orbital radiotherapy has been advocated for decades, and 121 
older RCTs demonstrated that this was more effective when used in combination with 122 
corticosteroids(19, 20). However, subsequent studies either questioned the role of orbital 123 
radiotherapy or concluded that its benefit was limited to improvement in oculomotility(21-124 
23). This has generated significant controversy, in particular due to concerns about the entry 125 
criteria, trial design and radiotherapy administration in Gorman et al’s paper(22), which has 126 
led to disparity in practice. Orbital radiotherapy has now been largely abandoned in North 127 
America, whereas in European centres, including the UK, it is still routinely used(6, 23-25).  128 
As it is administered daily over 2-3 weeks and patients are typically of working age, this also 129 
has significant implications for the use of healthcare resources and patients’ time. 130 
Furthermore, only two relatively small studies have evaluated the additional effect of 131 
radiotherapy when combined with a high-dose course of systemic corticosteroids(19, 20), and 132 
clinical outcomes beyond 24 weeks have rarely been reported for any intervention in thyroid 133 
eye disease. We therefore sought to evaluate the long-term benefit of orbital radiotherapy and 134 
antiproliferative immunosuppression with azathioprine in the context of sustained systemic 135 
corticosteroid treatment for active moderate-to-severe thyroid eye disease . 136 
 137 
Methods 138 
Study design and participants 139 
We undertook this factorial design multicentre RCT in 6 centres in the UK. Patients  aged 20-140 
75 years were recruited to receive either azathioprine or placebo, plus either orbital 141 
radiotherapy or sham-radiotherapy, in combination with a standardised 24-week tapering oral 142 
prednisolone regime (Supplementary Table 1 and Supplementary Figure 1). In brief, all 143 
patients received an initial oral prednisolone dose of 80mg / day, which reduced to 20mg / 144 
day by 6 weeks, 10mg / day by 15 weeks and 5mg / day by 21 weeks. In accordance with the 145 
factorial design, study recruits were then randomly allocated into 4 groups 2 weeks after 146 
starting corticosteroids: azathioprine plus orbital radiotherapy, azathioprine plus sham-147 
radiotherapy, placebo plus orbital radiotherapy, or placebo plus sham-radiotherapy.  Full 148 
protocol details, including pre-specified primary and secondary outcome measures and 149 
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statistical analyses, have been previously peer-reviewed, published and are openly 150 
available(26). Trial registration was assigned retrospectively on 1 February 2006 151 
(ISRCTN22471573) following regulatory permissions, but prior to starting recruitment. 152 
 153 
Eligible patients had  a clinical activity score(27) ≥ 4 (worst eye) OR ≥ 2 (worst eye) with a 154 
history of proptosis or motility restriction of less than 6 months duration. They were also 155 
required to have a past or present history of abnormal thyroid function or a clinical diagnosis 156 
of thyroid eye disease made and confirmed by ≥2 muscle involvement on computed 157 
tomography or magnetic resonance imaging scan. The clinical activity score was scored out 158 
of 7 at the enrolment visit as its last 3 items (decreasing proptosis, decreasing visual acuity 159 
and decreasing eye movement) require a change in consecutive measurements to be 160 
calculated. This therefore cannot be done at the first assessment, but at all subsequent visits 161 
clinical activity score was scored out of 10.  If study recruits either had a < 6 month history 162 
of thyroid eye disease (defined as time since first symptom) or an improvement in any item 163 
of clinical activity score 2 weeks after starting the trial prednisolone regime, they were 164 
considered to have active disease and were randomised at the second trial visit. Key 165 
exclusion criteria included age <20 or >75 years, dysthyroid optic neuropathy, abnormal 166 
thiopurine methyltransferase activity and use of radioiodine or any immunomodulatory or 167 
cytotoxic drugs within the last 3 months (thyroidectomy was permitted).  168 
 169 
Randomisation and masking 170 
Patients’ eligibility for the study was assessed by the ophthalmic investigators at each trial 171 
centre. Allocation to treatment groups was by remote computerised randomisation and 172 
minimisation was used to reduce baseline disparities in potential confounding variables 173 
between trial interventions. These included smoking status at the time of thyroid eye disease 174 
diagnosis, thyroid status on enrolment, previous corticosteroid use, gender, disease 175 
severity, study centre, disease duration, age greater than 60 years and disease 176 
activity.  Patients, clinicians (both ophthalmic and endocrine) and data analysts were all 177 
masked. Only the trial co-ordinators (who monitored trial subjects blood results), pharmacists 178 
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and radiographers were unmasked. The success of masking for ophthalmic investigators and 179 
patients was assessed at study completion or withdrawal by asking them to declare which 180 
treatments they thought had been administered.  181 
 182 
Procedures 183 
Orbital radiotherapy 184 
Twenty gray (Gy) of radiation was administered to the retrobulbar orbit in 10-12 fractions 185 
over 2 to 3 weeks. Subjects receiving sham-radiotherapy also attended and underwent all the 186 
same procedures other than no radiation being delivered. Extensive effort was used across 187 
trial centres to ensure participants were unable to identify if they were receiving sham 188 
therapy, including use of a noise emitting device to simulate treatment administration(26) (for 189 
details of the radiotherapy procedures at each trial centre see Supplementary Text 2) 190 
 191 
Azathioprine 192 
Treatment dose varied between 100mg and 200mg daily (dispensed as 50 mg tablets), 193 
depending on body weight. Matched placebo tablets and packaging were used and the dose 194 
was adjusted according to a standard algorithm dependent on patients’ blood test results. 195 
Again, extensive effort was taken to ensure participants were unaware if they were receiving 196 
placebo, including identical blood tests and random placebo dose adjustments. To reduce the 197 
risk of serious adverse events, patients with abnormal thiopurine methyltransferase activity  198 
who are at increased risk of developing bone marrow suppression (low activity) or 199 
hepatotoxicity (high activity) with azathioprine were not enrolled.  200 
 201 
Follow-up and withdrawals 202 
Follow-up continued for a minimum of 48 weeks. Withdrawn subjects were returned to their 203 
referring ophthalmologist, however they were invited to attend assessment visits at the early 204 
(co-primary) and late (primary) outcome measure assessment times of 12 and 48 weeks to 205 
obtain data in accordance with the planned intention-to-treat analyses. Withdrawal criteria 206 
included worsening of disease (defined as a 2-point increase in clinical activity score or 207 
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development of optic neuropathy) and sustained blood test abnormalities (leucopenia, 208 
lymphopenia or abnormal liver function tests despite dose adjustment of azathioprine or 209 
placebo).  210 
 211 
Ethical approval and Trial Oversight 212 
The trial protocol was given a favourable opinion by the UK’s National Health Service South 213 
West Central Bristol Research Ethics Committee (REC reference: 05/Q2006/62). Clinical 214 
Trial Authorisation was given by the Medicines and Healthcare products Regulatory Agency 215 
(MHRA, reference: 03299/0003/001-0001; ISRCTN22471573) with the University of Bristol 216 
acting as the legal sponsor. Research governance and local Research and Development 217 
approvals were obtained across all sites prior to the start of recruitment. All participants gave 218 
written informed consent, and the conduct of the trial was subject to independent Data Safety 219 
Monitoring Committee and Trial Steering Committee review for the duration of the study.    220 
 221 
Outcomes 222 
As the principle objective of the trial was to evaluate treatment success and failure at the late 223 
time-point of 48 weeks, our primary outcome measures of disease severity binary clinical 224 
composite outcome measure (BOX 1) and Ophthalmopathy Index  (Supplementary Table 2) 225 
were selected to quantify the change in ocular deformity and visual dysfunction. An early, 226 
12-week, assessment of disease activity using the clinical activity score  was given lower 227 
priority and designated as a co-primary outcome (we expected that all participants would 228 
have a significant improvement in clinical activity score by 48 weeks in accordance with the 229 
natural history of the disease(28)). Secondary outcome measures included Total Eye Score  230 
Box 1 Calculation of the Binary Clinical Composite Outcome Measure   
Major Criteria   An improvement of ≥ 1 grade in diplopia score  An improvement of >8 degrees of eye movement in any direction   A reduction of ≥ 2 mm in proptosis  
 
Minor Criteria   A reduction of ≥ 2 mm in lid aperture   An improvement of ≥ 1 grade in soft tissue involvement  An improvement in best-corrected visual acuity of ≥ 1 line on the Snellen chart  Subjective improvement 
 
All items refer to the worst eye 
 
Response to treatment is calculated as follows  
Improved = improvement in ≥1 major criteria or ≥2 minor criteria  
No Change = improvement or deterioration in ≤1 minor criterion  
Worse = deterioration in ≥1 major or ≥2 minor criteria (even if other criteria improve) 
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(Supplementary Table 3) as an additional assessment of disease severity, patient-reported 231 
Graves’ Ophthalmopathy Quality of Life score and health economic indices.   232 
 233 
Statistical analyses 234 
Planned statistical analyses were pre-specified in our protocol paper, based on a sample size 235 
of 100 complete datasets at 48 weeks(26). These were undertaken according to CONSORT 236 
guidelines for RCTs. As required by the factorial design, the primary intention-to-treat 237 
analysis (ITT) combined the treatment groups to compare radiotherapy versus sham-238 
radiotherapy and azathioprine versus placebo for each of the two primary outcomes at 48 239 
weeks follow up. This analysis was made using multivariable regression models, adjusting 240 
for minimisation variables, the factorial design, and the value of the outcome variable at 241 
baseline. Statistical significance was defined in advance as a p-value of <0.05. Patients who 242 
had no outcome data for the primary analyses had data imputed using last observation carried 243 
forward if they had data available between 24-48 weeks. Analysis was performed for all 244 
primary outcomes (binary clinical composite outcome, ophthalmopathy index and clinical 245 
activity score).  Patients who withdrew from treatment due to side-effects, disease 246 
progression or personal preference, were encouraged to continue to attend for follow-up 247 
assessments and their data included in the intention-to-treat analyses. Since there were a large 248 
number of withdrawals from treatment (although most trial subjects still returned for 249 
assessment at the primary endpoint visit), a post-hoc as-per-protocol analysis was conducted 250 
including only patients who had not withdrawn and continued to receive their assigned 251 
treatment. Testing for interaction was performed using likelihood ratio tests. Additional 252 
sensitivity analyses were performed for the binary clinical composite outcome measure,  253 
including recoding those who withdrew due to deterioration, irrespective of their final status 254 
at 48 weeks (as they may have received alternative rescue therapy). The secondary outcome 255 
measures of Total Eye Score and Graves ophthalmopathy quality-of-life score were also 256 
compared across treatment groups, however patient-reported health economic analyses were 257 
not completed due to insufficient data.  All statistical analyses were undertaken using 258 
STATA version 12 (STATACORP, College Station, TX, USA).  259 
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Study Sponsor and role of the funding source 260 
The study sponsor was the University of Bristol. Funding was provided by the UK’s National 261 
Eye Research Centre, Above and Beyond and Moorfields Eye Charity supported by 262 
infrastructural investment from the National Institute for Health Research. The sponsor and 263 
funders had no role in the study design, in the collection, analysis, and interpretation of data, 264 
in the writing of the report or in the decision to submit the paper for publication. In addition, 265 
the corresponding author had full access to all of the data and the final responsibility to 266 
submit for publication (PNT RH CMD and RL had access to the raw data). 267 
 268 
Results 269 
Study Population 270 
126 people were recruited and randomised between February 2006 and October 2013 (71 271 
patients from Moorfields Eye Hospital, 34 from Bristol Eye Hospital, 7 from Manchester Eye 272 
Hospital, 5 from the Western Eye Hospital, 4 from University College London Hospital, 4 273 
from Gartnavel General Hospital and 1 from the University Hospital of Wales).  The flow of 274 
study participants is shown in Figure 1.  Data on both the primary outcomes at 48 weeks was 275 
provided by 103 participants, and these were analysed after data-lock (which included 276 
separate 3 year assessments on a minority of trial subjects) on 7th October 2016. Baseline 277 
characteristics of the minimisation variables by group are shown in Table 1. Individuals 278 
allocated to azathioprine had a relatively lower proportion of non-Caucasian patients (not a 279 
criterion used for minimisation).  280 
 281 
Intention-to-treat  analysis 282 
Binary Clinical Composite Outcome Measure (primary outcome) 283 
The difference in the binary clinical composite outcome measure  between individuals 284 
randomised to azathioprine versus placebo tablets was on the threshold of our pre-specified 285 
significant p-value of <0.05, but did not meet this (the adjusted OR(adj) of the binary clinical 286 
composite outcome measure’s improvement on azathioprine was 2·56; 95%CI 0·98, 6·66; 287 
p=0·05, Table 2 Figure 2A). In contrast, there was no improvement with orbital radiotherapy 288 
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(OR(adj) =0·89, 95%CI 0·36, 2·23, p=0·80). Also, with regard to the factorial design, there 289 
was no evidence of interaction between azathioprine and radiotherapy (pint = 0·86) and the 290 
combination of azathioprine and orbital radiotherapy did not offer additional advantage over 291 
azathioprine alone. An overview of the impact on the binary clinical composite outcome 292 
measure of azathioprine and orbital radiotherapy is shown in Supplementary Figure 293 
2A+2B. Furthermore, additional sensitivity analyses in which withdrawn patients were coded 294 
to unfavourable outcomes regardless of their status at 48 weeks enhanced rather than lessened 295 
the improvement observed with azathioprine treatment (OR(adj) 3·65; 95%CI 1·34, 9·86; 296 
p=0·01) ( Supplementary Table 4). 297 
 298 
Ophthalmopathy Index (primary outcome) 299 
Analysis of all patients revealed that the ophthalmopathy index fell between week 12 (mean 300 
9.15, SD 0.39) and week 48 (mean 8.43, SD 0.38, p=0.04). No additional benefits were seen 301 
with either azathioprine or orbital radiotherapy. Individuals randomised to azathioprine had 302 
an adjusted Beta (B)(adj) of 0·46 (95%CI -1·04, 1·95; p=0·55) and in those randomised to 303 
orbital radiotherapy B(adj) was -0·89 (95%CI -2·34, 0·56; p=0·23) (Table 2). There was also 304 
no evidence of an interaction between azathioprine and radiotherapy in their effect on 305 
ophthalmopathy index (pint = 0·51). 306 
 307 
Clinical Activity Score  (co-primary outcome) 308 
Across all subjects, substantial improvement in median clinical activity score was seen over 309 
the study period from 5 (IQR 4 - 5) at baseline to 3 (IQR 2- 4; p<0·0001) at week 12, and 2 310 
(IQR 1-3; p<0·0001) at week 48 (Figure 2B, 2C). The majority of patients n=97 (70·0%) 311 
improved their clinical activity score by week 12 and 96 (98%) of the 98 patients with 312 
clinical activity score data at 48 weeks showed improvement in their clinical activity score 313 
versus baseline. No difference in the change in clinical activity score at 12 weeks was 314 
observed between individuals who received treatment with azathioprine versus not receiving 315 
azathioprine, or who received radiotherapy versus sham radiotherapy B(adj)= -0·01 (95%CI -316 
0·69, 0·68; p=0·99 – Table 2). There was no interaction between azathioprine and 317 
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radiotherapy in their effect on clinical activity score (pint= 0·48). There was also no evidence 318 
that azathioprine or orbital radiotherapy improved clinical activity score  at week 48 319 
(Supplementary Table 5).  320 
  321 
Total Eye Score (secondary outcome) 322 
Total Eye Score improved considerably over the study period with a mean at baseline of 15·1 323 
(95%CI 13·8, 16·3) falling to a mean of 9·36 (95%CI 8·12, 10·6; p <0·0001), but this was 324 
not affected by the addition of either azathioprine or orbital radiotherapy (Supplementary 325 
Table 6).  326 
 327 
Graves Ophthalmopathy Quality of Life (secondary outcome) 328 
Across all subjects, mean Graves ophthalmopathy quality of life visual function was higher 329 
(improved) at 12 weeks than at baseline (71·5 - 95%CI 66·1, 76·9 vs 64·1 - 95%CI 58·5, 330 
70·0; p=0·002), and at week 48 (75·5 - 95%CI 70·3, 80·7; p<0·001 versus baseline). Graves 331 
ophthalmopathy quality of life visual appearance was also higher at 12 weeks than at baseline 332 
(58·0 - 95%CI 52·5, 63·5 vs 53·2 - 95%CI 47·9, 58·6; p=0·007) and at week 48 (61·3 - 333 
95%CI 55·6, 67·1; p=0·001 versus baseline). Individuals who had an improvement in the 334 
binary clinical composite measure at week 48 had a higher Graves ophthalmopathy quality of 335 
life visual function (B=17·9 - 95%CI 7·07, 28·6; p<0·001) and a higher Graves 336 
ophthalmopathy quality of life visual appearance (B(adj)=11·5 - 95%CI 0·60, 23·6; p=0·06). 337 
There was no clear benefit from the addition of either azathioprine or orbital radiotherapy 338 
with regard to long-term Graves ophthalmopathy quality of life visual function or visual 339 
appearance (Supplementary Table 7, Supplementary Figure 3).   340 
 341 
As-per-protocol analysis 342 
Sixty individuals did not withdraw from study treatment before 48 weeks, completed their 343 
therapy period as allocated and were included in the as-per-protocol analysis. Ten of these 344 
patients were randomised to azathioprine and sham-radiotherapy, 17 were randomised to 345 
orbital radiotherapy and placebo alone, 12 were randomised to azathioprine and orbital 346 
14 
 
 
 
 
 
radiotherapy and 21 were randomised to sham-radiotherapy and placebo. Individuals in the 347 
as-per-protocol analysis appeared similar at baseline to those who were withdrawn from 348 
study treatment, although there was a higher percentage of non-Caucasians in those recruited 349 
from the larger study centres (Supplementary Table 8). 350 
 351 
In the as-per-protocol analysis, individuals randomised to receive azathioprine (n=22) had a 352 
higher odds ratio of improvement in their disease severity measured by the primary binary 353 
clinical composite outcome measure at 48 weeks (OR(adj)=6·83, 95%CI 1·66, 28·1; p=0·008). 354 
No benefit was seen in individuals randomised to receive orbital radiotherapy (OR(adj) 1·32, 355 
95%CI 0·36, 4·84; p=0·67, Table 3 Figure 2A).  To assess the effect of the duration of 356 
exposure to azathioprine we also conducted a comparative analysis of patients who continued 357 
to receive their allocated treatments at 12 weeks (n=84), 24 weeks (n= 79) and 36 weeks 358 
(n=68). This indicated that benefit was observed with ≥24 weeks of azathioprine exposure 359 
(Figure 2A, Supplementary Table 9 and Supplementary Figure 2A). Individuals 360 
receiving azathioprine also had a modest improvement in total eye score (B(adj)= -3·23, 361 
95%CI -6·42, 0·03; p=0·05, Supplementary Table 6). However, the as-per-protocol analysis 362 
did not reveal any benefit in ophthalmopathy index, clinical activity score or Graves 363 
ophthalmopathy quality of life of being randomised to receive either azathioprine or orbital 364 
radiotherapy (Table 3).  365 
 366 
Withdrawals from the study  367 
There was a high number of patients who withdrew from there allocated treatment (n=66, 368 
52·4%) (Figure 1), but the majority of these (n=45, 68.2%) returned for primary outcome 369 
evaluation. Twenty-five withdrawals were within the first 12 weeks (Figure 3). Withdrawals 370 
were less in non-Caucasians and in participants at two of the study centres (Moorfields and 371 
Bristol Eye Hospitals). Before 48 weeks there were 40 withdrawals in those randomised to 372 
receive azathioprine and 34 withdrawals in those randomised to receive orbital radiotherapy. 373 
Overall, 103 participants provided outcome data, of which 84 completed their allocated 374 
treatment of  radiotherapy or sham-radiotherapy, and 57 continued to take azathioprine or 375 
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placebo until 48 weeks.  Participants randomised to receive azathioprine had increased odds 376 
of withdrawal compared to those who did not OR(adj)=2·82 (95%CI 1·23, 6·45) p=0·01 377 
(Supplementary Table 10). The reasons for withdrawal are presented in Supplementary 378 
Figure 4. Patients receiving azathioprine had an increased odds of withdrawal due to 379 
precautionary blood test abnormalities or side effects OR=9·10 (95%CI 2·60, 31·9) p=0.001 380 
(Supplementary Table 11). However, unlike patients receiving placebo, patients taking 381 
azathioprine did not withdraw due to deterioration following cessation of steroid treatment at 382 
24 weeks (Figure 3C).  No baseline characteristics predicted withdrawal due to either 383 
azathioprine or orbital radiotherapy although the highest odds of withdrawal for disease 384 
deterioration was in the sham-radiotherapy and placebo group (Supplementary Table 12). 385 
There was no evidence of bias between treatment groups with regard to failure to provide 386 
data at 48 weeks (Supplementary Table 13 and Supplementary Table 14). 387 
 388 
Rescue therapy (including surgery) and adverse events 389 
Twenty-one (47%) of the trial subjects who withdrew from study treatment but provided 390 
outcome data were documented to have received additional therapy (Supplementary Table 391 
15). In most cases this was additional steroid therapy continuing until the endpoint of the 392 
study (week 48). Surgery was however required in 5 individuals, 3 of whom were in the 393 
azathioprine group (3 orbital decompressions, 1 lid surgery and 1 strabismus correction).  The 394 
number of individuals experiencing an adverse event did not differ across the treatment 395 
groups (azathioprine N=161, radiotherapy N=156). (Supplementary Table 16 and 396 
Supplementary Table 17).  397 
 398 
Masking 399 
Of the 69 patients and 71 doctors who recorded their perceived trial allocation for 400 
azathioprine or placebo on study completion or withdrawal, 30 patients (43%) and 29 doctors 401 
(41%) were incorrect. For radiotherapy and sham-radiotherapy, of the 70 patients and 67 402 
doctors, 23 patients (33%)  and 33 doctors (49%) were incorrect. 403 
 404 
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Discussion 405 
CIRTED fulfilled its target sample size, with more than 100 complete data sets at 48 weeks. 406 
Improvement in our primary, co-primary and secondary outcome measures (binary clinical 407 
composite outcome measure, clinical activity score and Graves ophthalmopathy quality-of- 408 
life score) across all groups confirmed the previously reported benefits of high dose systemic 409 
corticosteroid therapy in active moderate-to-severe thyroid eye disease (Figures 2B and 2C). 410 
In this context, orbital radiotherapy did not confer additional patient benefit in any pre-411 
specified outcome measure either in the short (12-week) or longer term (48-week). 412 
Radiotherapy was delivered early in the treatment (before 12 weeks); hence it is unlikely that 413 
this result is significantly confounded by the high withdrawal rate later in the treatment 414 
course.  415 
 416 
Less strong conclusions can be drawn with regard to azathioprine as comparatively few 417 
patients completed the full course of treatment. Nonetheless, the improvement in the binary 418 
clinical composite outcome measure observed in the azathioprine-treated group of subjects 419 
that was on the threshold of statistical significance in our intention-to-treat analysis (p=0.05) 420 
is likely to be real as the effect was sustained or enhanced in our sensitivity analyses 421 
(Supplementary Table 4, Supplementary Table 9). This is reinforced by the post-hoc as-422 
per-protocol analysis results which showed substantial benefit in favour of azathioprine 423 
(OR(adj)=6·83 p=0·008).  Of note, patient outcomes improved particularly in those receiving 424 
azathioprine for 24 weeks or more (figure 3A). Since steroid therapy was stopped at 24 425 
weeks (as is common practice in thyroid eye disease), this suggests that the key benefit of 426 
azathioprine is to prevent relapse after withdrawal of steroids. This observation is consistent 427 
with the generally recognised role of azathioprine as a steroid-sparing agent, used to prevent 428 
relapse in other autoimmune conditions, and this is further reinforced by the findings of the 429 
MINGO study using an alternative antiproliferative agent (mycophenolate sodium) in thyroid 430 
eye disease. Furthermore, this view is supported by analysis of the binary clinical composite 431 
outcome measure components indicating that azathioprine did not increase major 432 
improvement rates overall but did reduce major deterioration in the binary clinical composite 433 
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outcome measure (p=0.004, Supplementary Figure 2A), plus the observation that late 434 
withdrawal (after 24 weeks) due to deterioration was not seen in patients treated with 435 
azathioprine (Figure 3C).  436 
 437 
A major feature of this study was the high rate of withdrawal from patients’ allocated 438 
treatment. In all study groups, early withdrawals (before 24 weeks) due to disease 439 
deterioration were seen as the steroid dose was reduced and this was not mitigated by orbital 440 
radiotherapy (Figure 3C). Our masked protocol necessarily set strict thresholds for 441 
withdrawal due to abnormal monitoring blood tests (white cell counts and liver function), 442 
which together with treatment side-effects led to more common withdrawals in those 443 
allocated to azathioprine (Figure 3B). Hence, it is likely that in usual clinical practice 444 
azathioprine treatment would be continued in a higher percentage of patients.  Importantly, 445 
many of those withdrawing from treatment still completed their study follow-up visits until 446 
the primary endpoint (48 weeks), resulting in the outcomes for over 80% of randomised 447 
subjects being available for our intention-to-treat analysis. 448 
 449 
The other key methodological point to consider is our use of two primary outcome measures 450 
at 48 weeks. As we have previously published (26), this was because of the lack of fully 451 
validated long-term disease severity measures in thyroid eye disease. We also wished to 452 
mitigate the theoretical limitations of composite binary scoring systems, in particular with 453 
regard to baseline variability between treatment groups, by using a continuous variable with 454 
regression analyses in mind. However, our minimisation strategy was successful in balancing 455 
baseline features across trial arms and the binary clinical composite outcome measure has 456 
since become the preferred end-point for thyroid eye disease studies as it is more sensitive to 457 
change(21, 23). We have therefore focused on this rather than the ophthalmopathy index 458 
which has not been a primary endpoint in other recent trials.  459 
 460 
The key strengths of this RCT include the use of minimisation, low rates of loss-to-follow-up 461 
(including of withdrawn patients) and the success of our extensive efforts to mask both 462 
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azathioprine and radiotherapy treatment allocation to both the patients and clinicians 463 
(including the use of sham radiotherapy). In addition, we observed no evidence of interaction 464 
between the two interventions (radiotherapy and azathioprine), which is supportive of our 465 
choice of a factorial design. Conversely, a major limitation of our study was the high 466 
withdrawal rate, particularly for those randomised to receive azathioprine. Therefore, our 467 
conclusions with regard to the efficacy of this treatment need to be interpreted with caution. 468 
We also permitted patients to enrol in the trial and start systemic corticosteroid therapy 469 
before their thyroid function tests were normalised. This potentially confounds the 470 
interpretation of our data with the benefit of returning to euthyroidism, but we judged 471 
intervening with immunosuppression in the early active phase of disease to outweigh this 472 
risk. Furthermore, given that demonstration of clinical improvement following a 2-week 473 
course of high-dose oral steroids was a key entry criterion, our results cannot be extrapolated 474 
to infer the value of radiotherapy or azathioprine in patients with steroid refractory disease. 475 
Oral corticosteroid therapy was used in this study and given to all study participants as this 476 
was the standard of care in the study centres at the time of trial initiation and remains 477 
commonly prescribed in many regions of the world including North America (29).  478 
 479 
In summary, our results suggest that low-dose orbital radiotherapy confers no additional short 480 
or long-term treatment benefit when combined with a six-month reducing course of oral 481 
corticosteroids. Our findings with regard to azathioprine are less definitive, but taken together 482 
indicate that, if tolerated, azathioprine improves 48-week clinical outcomes in patients with 483 
active moderate-to-severe thyroid eye disease. This supports the use of long-term 484 
antiproliferative treatments in combination with systemic corticosteroids for the treatment of 485 
active moderate-to-severe thyroid eye disease, consistent with established practice in other 486 
autoimmune conditions.   487 
 488 
  489 
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Table and figure headings 490 
Table 1  Characteristics of the 4 trial groups 491 
Table 2  Intention to treat analysis Binary Composite Clinical Outcome Measure, 492 
Ophthalmopathy Index and Change in Clinical Activity Score  493 
Table 3  As per protocol analysis Binary Composite Clinical Outcome Measure, 494 
Ophthalmopathy Index and Change in Clinical Activity Score  495 
 496 
Figure 1  Consort Diagram  497 
Figure 2A  Odds ratio of having an improved Binary Composite Clinical Outcome 498 
Measure score by treatment and duration in study 499 
Figure 2B  Boxplot of Clinical Activity Score at baseline, week 12 and week 48 by 500 
whether a participant was randomised to azathioprine   501 
Figure 2C  Boxplot of Clinical Activity Score at baseline, week 12 and week 48 by 502 
whether a participant was randomised to radiotherapy   503 
Figure 3A  Kaplan Meier survival showing withdrawals from treatment (all reasons)   504 
Figure 3B  Kaplan Meier survival showing withdrawals from treatment (side effects and 505 
abnormal blood results) 506 
Figure 3C  Kaplan Meier survival showing withdrawals from treatment (deterioration) 507 
508 
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